Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

A Study of the Safety and Tolerability of MEDI-551 in Scleroderma

Study:

A Phase 1, Randomized, Double-blind, Placebo-controlled Study of the Safety and Tolerability of MEDI-551 in Scleroderma

Rationale:

n/a

Purpose:

The primary objective of this study is to evaluate the safety and tolerability of intravenously administered MEDI-551 over escalating single doses in adult subjects with Scleroderma

Study Status: Recruiting

Recruiting:
Tara Barker 216-445-6139 barkert2@ccf.org

Condition Intervention Phase
Scleroderma Biological: MEDI-551
Biological: Placebo
Biological: MEDI-551
Biological: MEDI-551
Biological: MEDI-551
Other: Placebo
Phase 1

Verified by MedImmune LLC August, 2011

Sponsored by: MedImmune LLC
Information provided by: MedImmune LLC
ClinicalTrials.gov identifier: NCT00946699

Study Type: Interventional

Study Design: Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Cleveland Clinic Foundation
Cleveland, Ohio 44195
United States

Dominique Ethgen, M.D.., Study Director

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site